



**Apixaban
Accord**

accord

10 7208 0 6028463

accord

PATIENT ALERT CARD

Apixaban Accord (apixaban) Patient Alert Card

**This card should be with you / the child
/ the caregiver at all times**

**Show this card to the pharmacist,
dentist and any other healthcare
professionals before treatment.**

**I am under anticoagulation treatment
with Apixaban Accord (apixaban) to
prevent blood clots**

**Please complete this section or ask the
doctor to do it**

Name:

Birth Date:

Indication:

Weight:

Dose: mg twice daily

Doctor's Name:

Doctor's telephone:

Information for patients/ caregivers

- Take / give Apixaban Accord regularly as instructed. If you miss a morning dose, take / give it as soon as you remember and it may be taken together with the evening dose. A missed evening dose can only be taken during the same evening. Do not take two doses the next morning, instead continue to follow the dosing Schedule twice daily as recommended on the next day.
- Do not stop taking / give Apixaban Accord without talking to the doctor, as you are / the patient is at risk of suffering a stroke / blood Clot or other complications.
- Apixaban Accord helps to thin the blood. However, this may increase the risk of bleeding.
- Signs and symptoms of bleeding include bruising or bleeding under the skin, tar-coloured stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood.
- If the bleeding does not stop on its own, **seek medical attention immediately.**
- If you / the patient need(s) surgery or any invasive procedure, inform the doctor that you are / the patient is taking Apixaban Accord.

Information for healthcare professionals

- Apixaban Accord (apixaban) is an oral anticoagulant acting by direct selective inhibition of factor Xa.
- Apixaban Accord may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately.
- Treatment with Apixaban Accord does not require routine monitoring of exposure. A calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and emergency surgery (prothrombin time (PT), international normalised ratio (INR) and activated partial thromboplastin time (aPTT) clotting tests are not recommended) – see SmPC.
- An agent to reverse the anti-factor Xa activity of apixaban is available for adults, however, its safety and efficacy have not been established in paediatric patients (refer to the summary of product characteristics of andexanet alfa).

Version 2. Date of HPRA approval:
October 2025